Improving risk evaluation and outcomes in paediatric acute lymphoblastic leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1057746

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and high risk genetic changes in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $798,022.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute lymphoblastic leukaemia (ALL) | central nervous system (CNS) diseases | chemotherapy treatment effects | high risk | minimal residual disease | pharmacokinetics | relapse prevention | side-effects | survival analysis | transplantation

Related Links